Home	Quick Product Lists	Contact LC Labs	Login/Register	My Account	View Cart
In Business 29 Years - Since 1980		THE CURRENT TIME at LC Labs is:

P-6866 Prasugrel, Free Base, >99%

[CS-747] [Effient] [Efient] [LY-640315] [CS 747] [CS747] [LY 640315] [LY640315]

M.W. 373.44

C20H20FNO3S

[150322-43-3]

M.I. 14:  10215

Storage:  Store at or below -20 ºC.  Solubility:  Soluble in DMSO at 25 mg/mL with slight warming; soluble in ethanol at 5 mg/mL with slight warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility.  Disposal:  A

Find and View a Certificate of Analysis for this product

View the MSDS for this product

• Prasugrel is an oral third-generation thienopyridine prodrug of R-138727, which is a P2Y12 purinergic receptor modulator and functions as an inhibitor of platelet activation and aggregation-thrombolysis.  Motovska, Z. and Widimsky, P.  "Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel."  Vasc. Health Risk Manag. 5:  475-481 (2009).

• Prasugrel is a prodrug and is itself inactive in vitro.  In vivo it is absorbed and rapidly converted to the active form of the drug (R-138727).  Farid, N.A., et al.  "The disposition of prasugrel, a novel thienopyridine, in humans."  Drug Metab. Dispos. 35:  1096-1104 (2007).

• R-138727, the active metabolite of prasugrel, binds to the P2Y12 purinergic receptor specifically and irreversibly, and inhibits ADP-mediated platelet activation and aggregation for the life of the platelet.  Jakubowski, J.A., et al.  "Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile."  Cardiovasc. Drug Rev. 25:  357-374 (2007).

• Prasugrel was more consistent and potent than clopidogrel among patients treated with cardiac catheterization and percutaneous coronary intervention.  Wiviott, S.D., et al.  "Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial."  Circulation 116:  2923-2932 (2007).

• Prasugrel reduced early and late stent thrombosis in patients with acute coronary syndromes, irrespective of stent type.  Wiviott, S.D., et al.  "Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial."  Lancet 371:  1353-1363 (2008).

• Prasugrel is the active ingredient in the drug sold under the trade name Effient® in the United States and Efient® in Europe.  This drug has been approved in at least one country for use in patients with acute coronary syndromes for percutaneous coronary intervention (PCI).  NOTE:  The prasugrel product sold by LC Laboratories is NOT Effient® nor Efient® and is NOT for human use.

• Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.

• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.

• Not available in some countries; not available to some institutions; not available for some uses.